{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:13:34Z","timestamp":1771330414063,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473014"],"award-info":[{"award-number":["81473014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772540"],"award-info":[{"award-number":["81772540"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Province","award":["87316004"],"award-info":[{"award-number":["87316004"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bbrc.2018.06.157","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T10:24:31Z","timestamp":1530872671000},"page":"408-413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Polymorphisms of ABCG2 and its impact on clinical relevance"],"prefix":"10.1016","volume":"503","author":[{"given":"Wenji","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2018.06.157_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev.cb.08.110192.000435","article-title":"ABC transporters: from microorganisms to man","volume":"8","author":"Higgins","year":"1992","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gr.184901","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"11","author":"Dean","year":"2001","journal-title":"Genome Res."},{"key":"10.1016\/j.bbrc.2018.06.157_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: a perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2018.06.157_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/bbrc.2001.5130","article-title":"Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells","volume":"285","author":"Ozvegy","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2018.06.157_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1242\/jcs.01729","article-title":"Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2","volume":"118","author":"Henriksen","year":"2005","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.bbrc.2018.06.157_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ijc.10100","article-title":"Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization","volume":"97","author":"Kage","year":"2002","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.bbrc.2018.06.157_bib7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1006\/jmbi.1999.3489","article-title":"The GxxxG motif: a framework for transmembrane helix-helix association","volume":"296","author":"Russ","year":"2000","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib8","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1021\/bi0497953","article-title":"Mutational analysis of ABCG2: role of the GXXXG motif","volume":"43","author":"Polgar","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2018.06.157_bib9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature22345","article-title":"Structure of the human multidrug transporter ABCG2","volume":"546","author":"Taylor","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2018.06.157_bib10","doi-asserted-by":"crossref","first-page":"36926","DOI":"10.1074\/jbc.M502937200","article-title":"Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2","volume":"280","author":"Henriksen","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2018.06.157_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.biochem.73.011303.073626","article-title":"ATP-binding cassette transporters in bacteria","volume":"73","author":"Davidson","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbrc.2018.06.157_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygeno.2006.03.001","article-title":"Evolution of the vertebrate ABC gene family: analysis of gene birth and death","volume":"88","author":"Annilo","year":"2006","journal-title":"Genomics"},{"key":"10.1016\/j.bbrc.2018.06.157_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2017.10.004","article-title":"BCRP\/ABCG2 and high-alert medications: biochemical, pharmacokinetic, pharmacogenetic, and clinical implications","volume":"147","author":"Hira","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2005.04.039","article-title":"Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development","volume":"234","author":"Yanase","year":"2006","journal-title":"Canc. Lett."},{"key":"10.1016\/j.bbrc.2018.06.157_bib15","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/cbt.322","article-title":"Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR\/BCRP\/ABCP1)","volume":"1","author":"Honjo","year":"2002","journal-title":"Canc. Biol. Ther."},{"key":"10.1016\/j.bbrc.2018.06.157_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1349-7006.2005.00081.x","article-title":"Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics\/pharmacodynamics","volume":"96","author":"Sugimoto","year":"2005","journal-title":"Canc. Sci."},{"key":"10.1016\/j.bbrc.2018.06.157_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.pharmthera.2006.04.009","article-title":"Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs","volume":"112","author":"Cascorbi","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2018.06.157_bib18","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1023\/B:PHAM.0000045245.21637.d4","article-title":"Functional analysis of SNPs variants of BCRP\/ABCG2","volume":"21","author":"Kondo","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbrc.2018.06.157_bib19","first-page":"611","article-title":"C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance","volume":"1","author":"Imai","year":"2002","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.bbrc.2018.06.157_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2133\/dmpk.18.212","article-title":"Eight novel single nucleotide polymorphisms in ABCG2\/BCRP in Japanese cancer patients administered irinotacan","volume":"18","author":"Itoda","year":"2003","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.bbrc.2018.06.157_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.104.001628","article-title":"Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta","volume":"33","author":"Kobayashi","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbrc.2018.06.157_bib22","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1158\/1078-0432.CCR-04-0144","article-title":"ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition","volume":"10","author":"de Jong","year":"2004","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bbrc.2018.06.157_bib23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ijc.11669","article-title":"Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2","volume":"109","author":"Mizuarai","year":"2004","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.bbrc.2018.06.157_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00280-004-0931-x","article-title":"Single nucleotide polymorphisms modify the transporter activity of ABCG2","volume":"56","author":"Morisaki","year":"2005","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib25","first-page":"53","article-title":"Human ABC transporter ABCG2\/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics","volume":"7","author":"Noguchi","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.bbrc.2018.06.157_bib26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1042\/BJ20071229","article-title":"Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2","volume":"411","author":"Nakagawa","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2018.06.157_bib27","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11095-008-9752-7","article-title":"Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations","volume":"26","author":"Furukawa","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbrc.2018.06.157_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14728222.2018.1420167","article-title":"ABCG2 as a therapeutic target candidate for gout","volume":"22","author":"Fujita","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbrc.2018.06.157_bib29","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.1073\/pnas.0901249106","article-title":"Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout","volume":"106","author":"Woodward","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2018.06.157_bib30","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.3899\/jrheum.140126","article-title":"Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion","volume":"41","author":"Torres","year":"2014","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib31","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1080\/15257770.2011.627902","article-title":"Identification of ABCG2 dysfunction as a major factor contributing to gout","volume":"30","author":"Matsuo","year":"2011","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.bbrc.2018.06.157_bib32","doi-asserted-by":"crossref","first-page":"9149","DOI":"10.3390\/ijms15059149","article-title":"Functional polymorphisms of the ABCG2 gene are associated with gout disease in the Chinese Han male population","volume":"15","author":"Zhou","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2018.06.157_bib33","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3904\/kjim.2015.30.6.913","article-title":"Genetic analysis of ABCG2 and SLC2A9 gene polymorphisms in gouty arthritis in a Korean population","volume":"30","author":"Kim","year":"2015","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.bbrc.2018.06.157_bib34","first-page":"9812","article-title":"A\u00a0meta-analysis of the associations between the Q141K and Q126X ABCG2 gene variants and gout risk","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib35","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/aje\/kws330","article-title":"Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study","volume":"177","author":"Zhang","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/tpj.2015.101","article-title":"ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout","volume":"17","author":"Roberts","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.bbrc.2018.06.157_bib37","first-page":"79","article-title":"Role of Slc2a9 and Abcg2 gene polymorphisms in origin of hyperuricemia and gout","author":"Fadieieva","year":"2016","journal-title":"Georgian Med. News"},{"key":"10.1016\/j.bbrc.2018.06.157_bib38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3899\/jrheum.130870","article-title":"Joint effects of alcohol consumption and ABCG2 Q141K on chronic tophaceous gout risk","volume":"41","author":"Tu","year":"2014","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10067-015-3105-9","article-title":"Genetic variation in the ABCG2 gene is associated with gout risk in the Chinese Han population","volume":"35","author":"Jiri","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/FPC.0000000000000022","article-title":"Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line","volume":"24","author":"Skoglund","year":"2014","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.bbrc.2018.06.157_bib41","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bbrc.2018.06.157_bib42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.bbrc.2018.06.157_bib43","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib44","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.18632\/oncotarget.1050","article-title":"High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients","volume":"4","author":"Delord","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2018.06.157_bib45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs-2016-0103","article-title":"Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis","volume":"18","author":"Jiang","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bbrc.2018.06.157_bib46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s13277-015-3874-4","article-title":"Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia","volume":"37","author":"Salimizand","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.bbrc.2018.06.157_bib47","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/ijc.23956","article-title":"Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients","volume":"124","author":"Muller","year":"2009","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.bbrc.2018.06.157_bib48","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COC.0b013e318297f333","article-title":"Clinical significance of ABCG2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy","volume":"38","author":"Kim","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/pgs.10.172","article-title":"Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients","volume":"12","author":"Lemos","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bbrc.2018.06.157_bib50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40262-013-0058-5","article-title":"Population pharmacokinetics\/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer","volume":"52","author":"Fukudo","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbrc.2018.06.157_bib51","first-page":"43","article-title":"Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients","volume":"15","author":"Chen","year":"2015","journal-title":"Canc. Cell Int."},{"key":"10.1016\/j.bbrc.2018.06.157_bib52","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1186\/s12885-018-4471-x","article-title":"Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy","volume":"18","author":"Limviphuvadh","year":"2018","journal-title":"BMC Canc."},{"key":"10.1016\/j.bbrc.2018.06.157_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148177","article-title":"Association study of a functional variant on ABCG2 gene with sunitinib-induced severe adverse drug reaction","volume":"11","author":"Low","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2018.06.157_bib54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00280-014-2630-6","article-title":"Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor","volume":"75","author":"Koo","year":"2015","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib55","doi-asserted-by":"crossref","first-page":"7901","DOI":"10.1007\/s13277-015-4679-1","article-title":"Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer","volume":"37","author":"Ghafouri","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.bbrc.2018.06.157_bib56","doi-asserted-by":"crossref","first-page":"279109","DOI":"10.1155\/2015\/279109","article-title":"Genetic variations in ABCG2 gene predict breast carcinoma susceptibility and clinical outcomes after treatment with anthracycline-based chemotherapy","volume":"2015","author":"Wu","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.bbrc.2018.06.157_bib57","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s12032-013-0802-6","article-title":"Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer","volume":"31","author":"Zhao","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bbrc.2018.06.157_bib58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.dmpk.2015.05.002","article-title":"Polymorphisms of ABCG2, ABCB1 and HNF4alpha are associated with Lamotrigine trough concentrations in epilepsy patients","volume":"30","author":"Zhou","year":"2015","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.bbrc.2018.06.157_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/ahg.12258","article-title":"Association of ABCG2 polymorphisms with ischemic stroke in a Chinese population","author":"Liu","year":"2018","journal-title":"Ann. Hum. Genet."},{"key":"10.1016\/j.bbrc.2018.06.157_bib60","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2217\/pgs.15.47","article-title":"ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study","volume":"16","author":"Mirosevic Skvrce","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bbrc.2018.06.157_bib61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpt.362","article-title":"Pilot PET study to assess the functional interplay between ABCB1 and ABCG2 at the human blood-brain barrier","volume":"100","author":"Bauer","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2018.06.157_bib62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neulet.2013.06.044","article-title":"Association between the ABCG2 C421A polymorphism and Alzheimer's disease","volume":"550","author":"Feher","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbrc.2018.06.157_bib63","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.febslet.2004.03.123","article-title":"ABCG2-a transporter for all seasons","volume":"567","author":"Sarkadi","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbrc.2018.06.157_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1349-7006.2006.00371.x","article-title":"Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2","volume":"98","author":"Tamura","year":"2007","journal-title":"Canc. Sci."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X18314761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X18314761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:27:54Z","timestamp":1757762874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X18314761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0006291X18314761"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.06.157","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymorphisms of ABCG2 and its impact on clinical relevance","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.06.157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}